Japan and South Korea AI in Drug Discovery Market

According to latest research report published by MarketsandMarkets, the AI in Drug Discovery Market in Japan and South Korea by Offering (Software, Service), Technology (Machine Learning, Deep Learning), Application (Cardiovascular, Metabolic, Neurodegenerative), End User (Pharma, Biotech,CROs) - Global Forecasts to 2027, is expected to grow at a CAGR of 45.7% from 2022 to 2027.

AI-powered drug discovery platforms are being used to identify new drug targets, design new drugs, and optimize the drug development process. These platforms can screen large datasets of molecules to identify potential drug candidates, and they can also be used to predict the efficacy and toxicity of drugs. AI is also being used to develop new methods for manufacturing drugs, such as 3D printing of drugs.

The growth of this market is being driven by the following factors:

• Rising investments in healthcare: Both Japan and South Korea have been investing heavily in healthcare in recent years. This investment has led to the development of world-class healthcare infrastructures in these countries. The availability of such infrastructures has created a favorable environment for the growth of the AI in Drug Discovery Market.
• Increasing prevalence of chronic diseases: Chronic diseases such as cancer, diabetes, and cardiovascular diseases are a major cause of death and disability in Japan and South Korea. The increasing prevalence of these diseases is driving the demand for new and innovative drugs. AI-powered drug discovery platforms can help pharmaceutical companies to identify new drug targets and design new drugs more efficiently.
• Government support: Both the Japanese and South Korean governments are supportive of the development of new technologies in the healthcare sector. The governments of these countries have been providing financial and regulatory support to the development of AI-powered drug discovery platforms.

The AI in Drug Discovery Market in Japan and South Korea can be segmented by technology, application, end-user, and indication.

• By technology: The market can be segmented into target identification, drug design, and drug optimization.
• By application: the market is segmented into on-premise and cloud-based. Cloud-based analytics is the fastest-growing delivery mode in the healthcare industry. In 2022, the cloud-based analytics segment accounted for the largest share of the market.
• By end-user: The market can be segmented into pharmaceutical companies, contract research organizations (CROs), and academic institutions.
• By indication: The market can be segmented into cancer, cardiovascular diseases, neurological disorders, metabolic disorders, and others.

The machine learning segment is expected to be the largest segment of the market during the forecast period. This is due to the increasing adoption of machine learning algorithms for drug discovery. Machine learning algorithms can be used to screen large datasets of molecules to identify potential drug candidates.

The target identification segment is expected to be the fastest-growing segment of the market during the forecast period. This is due to the increasing demand for new and innovative drug targets. AI-powered drug discovery platforms can help pharmaceutical companies to identify new drug targets that are more likely to lead to the development of effective drugs.

The following are some of the key players in the AI in Drug Discovery Market in Japan and South Korea:

• Almac Discovery: Almac Discovery is a global contract research organization (CRO) that provides drug discovery services to pharmaceutical and biotechnology companies. The company has a strong track record of success in the development of new drugs using AI-powered drug discovery platforms.
• Insilico Medicine: Insilico Medicine is a pharmaceutical company that uses AI to design new drugs. The company has a proprietary platform that can screen large datasets of molecules to identify potential drug candidates.
• Exscientia: Exscientia is a pharmaceutical company that uses AI to design new drugs. The company has a proprietary platform that can predict the efficacy and toxicity of drugs.

Don’t miss out on business opportunities in Artificial Intelligence/AI in Drug Discovery Market. Speak to our analyst and gain crucial industry insights that will help your business grow.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]